| Chapter title |
Multimodality Therapy for NSCLC
|
|---|---|
| Chapter number | 7 |
| Book title |
Lung Cancer
|
| Published in |
Cancer treatment and research, January 2016
|
| DOI | 10.1007/978-3-319-40389-2_7 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-940387-8, 978-3-31-940389-2
|
| Authors |
Lingling Du, Saiama N. Waqar, Daniel Morgensztern, Du, Lingling, Waqar, Saiama N., Morgensztern, Daniel |
| Abstract |
The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage III NSCLC. New studies using induction therapy with erlotinib or crizotinib for molecularly selected patients and consolidation therapy with checkpoint inhibitors are currently ongoing, and the results are eagerly awaited. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 18% |
| Student > Postgraduate | 3 | 18% |
| Student > Bachelor | 2 | 12% |
| Student > Master | 2 | 12% |
| Student > Ph. D. Student | 1 | 6% |
| Other | 3 | 18% |
| Unknown | 3 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 29% |
| Agricultural and Biological Sciences | 1 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Unknown | 3 | 18% |